

1

2 **Systematic review and patient-level meta-analysis of SARS-CoV-2 viral**

3 **dynamics to model response to antiviral therapies**

4

5 Silke Gastine ¹, Juanita Pang ², Florencia A.T. Boshier ², Simon J. Carter ¹, Dagan O. Lonsdale ^{3,4}, Mario Cortina-Borja ⁵,
6 Ivan F.N. Hung ⁶, Judy Breuer ², Frank Kloprogge ⁷, Joseph F. Standing ¹

7

8 ¹ Infection, Immunity and Inflammation Research and Teaching Department, Great Ormond Street Institute of Child
9 Health, University College London, London, United Kingdom

10 ² Division of Infection and Immunity, University College London, London, United Kingdom

11 ³ Department of Clinical Pharmacology, St George's University of London, United Kingdom

12 ⁴ Department of Intensive Care, St George's University Hospitals NHS Foundation Trust, London, United Kingdom

13 ⁵ Population, Policy and Practice Research and Teaching Department, Great Ormond Street Institute of Child Health,
14 University College London, London, United Kingdom

15 ⁶ Division of Infectious Diseases, Department of Medicine, The University of Hong Kong, Hong Kong, China

16 ⁷ Institute for Global Health, University College London, London, United Kingdom

17

18 Running title: Covid Antiviral Modelling

19

20 Key words: SARS-CoV-2, COVID-19, viral dynamics, pharmacodynamics

21

22 SOURCE OF FUNDING

23 No specific funding was available for this work. Support at institution level came from the National Institute for Health
24 Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University
25 College London, and J.F.S. and F.K. were supported by United Kingdom Medical Research Council (MRC) Fellowships
26 (grants M008665 and P014534). JB receives funding from the NIHR UCL/UCLH Biomedical Research Centre. JP is
27 supported by a Rosetrees Trust PhD fellowship (M876). FTB is supported by a Wellcome Trust Collaborative Award
28 (203268) to JB.

29

30 DISCLOSURE OF CONFLICT OF INTEREST

31 The authors declared no competing interests for this work. As an Associate Editor of Clinical Pharmacology and
32 Therapeutics, Joseph F. Standing was not involved in the review or decision process for this paper.

33

34

35 Corresponding Author:

36 Dr Silke Gastine

37 Infection, Immunity & Inflammation, Great Ormond Street Institute of Child Health, University College London, London,
38 WC1N 1EH, United Kingdom

39 Email: s.gastine@ucl.ac.uk

40

41

42

43

44

45 ABSTRACT

46 SARS-CoV-2 viral loads change rapidly following symptom onset so to assess antivirals it is important to understand the
47 natural history and patient factors influencing this. We undertook an individual patient-level meta-analysis of SARS-CoV-2
48 viral dynamics in humans to describe viral dynamics and estimate the effects of antivirals used to-date. This systematic
49 review identified case reports, case series and clinical trial data from publications between 1/1/2020 and 31/5/2020
50 following PRISMA guidelines. A multivariable Cox proportional hazards regression model (Cox-PH) of time to viral
51 clearance was fitted to respiratory and stool samples. A simplified four parameter nonlinear mixed-effects (NLME) model
52 was fitted to viral load trajectories in all sampling sites and covariate modelling of respiratory viral dynamics was
53 performed to quantify time dependent drug effects. Patient-level data from 645 individuals (age 1 month-100 years) with
54 6316 viral loads were extracted. Model-based simulations of viral load trajectories in samples from the upper and lower
55 respiratory tract, stool, blood, urine, ocular secretions and breast milk were generated. Cox-PH modelling showed longer
56 time to viral clearance in older patients, males and those with more severe disease. Remdesivir was associated with faster
57 viral clearance (adjusted hazard ratio (AHR) = 9.19, $p < 0.001$), as well as interferon, particularly when combined with
58 ribavirin (AHR = 2.2, $p = 0.015$; AHR = 6.04, $p = 0.006$). Combination therapy should be further investigated. A viral
59 dynamic dataset and NLME model for designing and analysing antiviral trials has been established.

60 INTRODUCTION

61 Finding antivirals that target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will be crucial in managing
62 the ongoing pandemic. In addition to the development of novel agents, substantial efforts are underway to establish whether
63 currently available agents may be re-purposed¹. A key biomarker for clinical antiviral activity is viral load in bodily fluids
64 and assessing a drug's or drug combination's ability to reduce viral load is an important first step in identifying therapies
65 that influence clinical outcome.

66
67 To correctly assess antiviral activity, it is first necessary to understand viral load natural history. As a rapidly progressing,
68 primarily respiratory viral infection, SARS-CoV-2 elimination from the body seems to be mainly driven by a combination
69 of innate immune response and exhaustion of target cells available for infection². Observational cohort studies published to
70 date have shown that the rate of viral load decline seems slower in older patients, those with more severe disease and those
71 with comorbidities such as diabetes mellitus and immunosuppression^{3, 4, 5, 6}. Interpreting these observational studies
72 requires caution because patients have often received antiviral therapies. Due to the time point of initial infection being
73 unknown, assessing viral load in response to treatment must account for time since symptom onset⁷.

74
75 Since February 2020 case reports and case series of patient-level viral dynamics have been published, some of which report
76 dosing of antiviral drugs⁸. Clinical trials of antivirals and their association with viral load are also beginning to read out⁹.
77 Meanwhile large pragmatic trials of repurposed monotherapy antivirals have yet to find a clearly effective agent¹⁰. At this
78 crucial juncture, it is vital to develop a pharmacodynamic modelling framework that can be used to describe the natural
79 history of SARS-CoV-2 viral dynamics, make initial estimates on antiviral efficacy of agents used to-date, and to design
80 and evaluate Phase II trials using viral load as a biomarker.

81
82 This systematic review therefore aimed to search for case reports, case series and clinical trials reporting serial individual
83 patient-level SARS-CoV-2 viral load measurements in humans from any sampling site upon which an individual patient-
84 level meta-analysis was then performed. A nonlinear mixed effects (NLME) viral dynamic model was fitted to describe the
85 viral trajectories in each sampling site and to give a quantitative measure of viral dynamics. In data of sufficient quality, the

86 parameters of multivariable Cox proportional hazards regression models of time to viral clearance, and NLME models of
87 antiviral efficacy were estimated.

88 METHODS

89 **Protocol and registration**

90 The protocol for this systematic review and individual patient meta-analysis, which follows the PRISMA Individual Patient
91 Data systematic reviews guideline¹¹, was first published on 27/5/2020 at: [https://github.com/ucl-pharmacometrics/SARS-](https://github.com/ucl-pharmacometrics/SARS-CoV-2-viral-dynamic-meta-analysis)
92 [CoV-2-viral-dynamic-meta-analysis](https://github.com/ucl-pharmacometrics/SARS-CoV-2-viral-dynamic-meta-analysis). The final dataset and statistical analysis code are also published here. The review was
93 registered with PROSPERO (CRD42020189000).

94

95 **Eligibility criteria**

96 This study aimed to identify serial viral loads with time in human subjects infected with SARS-CoV-2 in order to describe
97 and model viral load trajectory. The inclusion criteria were therefore papers containing individual subject-level reports of
98 viral load with time, either since symptom onset or time since start of monitoring for asymptomatic subjects, and sampling
99 site. Authors of manuscripts describing summary statistics of viral load with time were contacted requesting participant
100 level data. Viral load was defined as either a value in copies/mL or a cycle threshold (Ct) value of an uncalibrated
101 polymerase chain reaction (PCR) assay.

102

103 **Overall search strategy**

104 Since SARS-CoV-2 was notified to the WHO on 31/12/2019, we did not expect to find relevant papers published prior to
105 this date. Hence, PubMed, EMBASE, medRxiv, and bioRxiv were searched with a date range of 1/1/2020 to 31/5/2020.
106 The following search terms were used for PubMed and EMBASE: (SARS-CoV-2 OR COVID OR coronavirus OR 2019-
107 nCoV) AND (viral load OR cycle threshold OR rtPCR OR real-time PCR OR viral kinetics OR viral dynamics OR
108 shedding OR detection OR clinical trial). Due to character limits in the search engine, the following search terms were used
109 for medRxiv and bioRxiv: (SARS-CoV-2 OR COVID-19 OR coronavirus) AND (viral load OR cycle threshold OR PCR
110 OR viral dynamics OR clinical trial).

111

112 After removing duplicates, two reviewers independently identified papers for full text screening, with any discrepancies
113 resolved by a third reviewer.

114

115 **Data extraction**

116 Viral loads were reported as either numerical values in tables, figures, or in viral load *versus* time plots. Where possible,
117 numerical values were copy-pasted directly into a comma separated value (csv) format from the source, whereas tabulated
118 numerical values contained in pdf images were extracted using <https://extractable.com/>. Viral loads reported in plots were
119 extracted using Web Plot Digitizer¹².

120

121 Each viral load was paired with a time since symptom onset or in asymptomatic subjects, the time since viral monitoring
122 started. Furthermore, sampling site and, if viral load not reported in copies/mL, the PCR assay including the primers used,
123 were extracted along with limit of quantification and limit of detection, if available. The following patient-level covariates
124 were extracted if available:

- 125 • Presence of fever >37.5 °C at any time (non-time varying covariate)
- 126 • age, where possible individual age but otherwise the study's reported central measure (e.g. mean, median)
- 127 • sex or the male/female ratio was extracted if patient-level data not reported
- 128 • need for and days of intensive care treatment
- 129 • need for and days of mechanical ventilation
- 130 • whether patient died and time to death from symptom onset.

131 In addition, a standardised disease score was constructed for each patient as follows:

132 0 - asymptomatic

133 1 - mild disease (fever, cough or other mild symptoms reported)

134 2 - moderate disease (in addition to mild criterion: need for supplemental oxygen /non-invasive ventilation)

135 3 - severe disease (requirement for mechanical ventilation)

136 All data were stored on a shared github repository, and standardised R-scripts took data from each paper to merge into a
137 single master dataset. A quality control (QC) check on viral load values and all covariates was performed for each paper by
138 an independent reviewer.

139

140 **Data quality assessment**

141 Viral load quality score

142 Two quality assessments were applied to each dataset. Firstly, the quality of viral load reporting was rated on a 1-3 scale.
143 The highest quality 1 was assigned to studies reporting viral load in copies/mL or reporting a calibration curve allowing for
144 direct conversion of Ct values to viral load. Quality 2 was assigned if viral load was reported in PCR Ct and primers used in
145 the assay were reported, but calibration data was missing. In this case a published calibration curve for that primer from
146 another source was used to convert to viral load in copies/mL^{13, 14}. Where more than one calibration curve was available for
147 the same primer the mean slope and intercept was used. The lowest (quality score 3) was assigned when viral load was
148 reported in PCR Ct but no further information was available on the PCR assay. In this instance a conversion to copies/mL
149 was made using the mean slope and intercepts from all calibration curves.

150

151 Drug quality score

152 The second quality assessment on a 3-point scale related to reporting of the antiviral drug therapy administered: which
153 drug(s) and upon which days did patients receive the drug(s). The highest quality 1 was assigned when it was reported
154 which days each patient received each drug, or these data were provided by corresponding authors. If it was reported that
155 no antiviral was administered this was also assigned quality 1. Quality 2 was assigned when antiviral drug treatment was
156 reported, but ascertaining which days the patient had received the drugs was not possible. The lowest category, quality 3,
157 was assigned when it was not possible to determine whether or not antivirals had been administered.

158

159 **Statistical analysis**

160 Primary analysis of time to viral clearance using Cox proportional hazards modelling

161 The primary analysis was conducted on observed time to viral clearance, which was analysed fitting Cox proportional
162 hazards regression models with adjusted hazard ratios estimated for each covariate. We verified the assumptions of
163 proportional hazards using the Therneau-Grambsch test.¹⁵ The data used for this analysis were limited to respiratory and
164 stool sampling sites only, as virus was found to be mostly undetectable at other sites. Furthermore, only data from patients
165 with known antiviral history (drug quality 1 and 2) were used. To assess the possible risk of bias in different drug and viral

166 load qualities, the analysis was repeated on two further subsets: Firstly, with only drug quality 1 and respiratory samples,
167 and secondly on assay quality 1 data only.

168

169 Time to viral load dropping below the limit of detection was modelled with Cox proportional hazards regression in R
170 (version 3.6.3)¹⁶. Where a single patient contributed samples from multiple sampling sites (e.g. upper respiratory and stool),
171 the time to the last site testing negative was used. Multivariable models for covariate effects on time to viral clearance were
172 fitted, with additional interaction terms for drug therapies included, where multiple antiviral agents were given
173 simultaneously. In studies reporting sex as a proportion of males, 10 000 datasets were simulated using the reported
174 fraction of males to randomly assign individuals to being male from the binomial distribution. The Cox proportional
175 hazards regression model was then fitted to each dataset and parameter estimates compared with the model, where
176 individual sex was assigned by rounding the fraction of males. Model parameter estimates were visualised using forest
177 plots.

178 Secondary analysis antiviral pharmacology model

179 The secondary analysis was to use a NLME model to quantify the increase in viral elimination rate with antiviral therapy.
180 This analysis used data only from respiratory samples and rated drug quality 1.

181 *Nonlinear mixed-effects (NLME) viral dynamic model*

182 Firstly, a descriptive analysis of all data was undertaken. A NLME viral dynamics model was fitted to the individual
183 patient-level viral load *versus* time data. The structural model was based on the general target cell limited model, which has
184 previously been used to describe respiratory viral infections^{7,17}. This model consists of three ordinary differential equations
185 relating to changes in uninfected target cells (T), infected target cells (I) and free virus (V) over time (t), as follows:

$$\frac{dT(t)}{dt} = -\beta T(t)V(t)$$

$$\frac{dI(t)}{dt} = \beta T(t)V(t) - \delta I(t)$$

$$\frac{dV(t)}{dt} = \rho I(t) - cV(t)$$

186 where β is the rate at which target cells become infected in the presence of virus, δ is the death rate of infected cells, ρ is the
187 rate of viral production from infected cells and c is the rate of clearance of free virus. This model is structurally

188 unidentifiable, as tested through the *IdentifiabilityAnalysis* package in Wolfram Mathematica 12.1 (Wolfram Research,
189 Illinois, USA)¹⁸, unless the initial condition for T , β , or ρ are known. Furthermore, the elimination rate of free virus (c) is
190 likely to be much faster than the death rate of infected cells (δ). Hence, by assuming a quasi-steady-state between I and V ,
191 and normalising the total cell number by the number of infected cells when observations begin ($t = 0$), it is then possible to
192 reduce the model to a structurally identifiable, two state ordinary differential equation model relating to the fraction (f) of
193 infected cells with time and infected cells as a proxy for viral load as follows¹⁹:

$$\frac{df(t)}{dt} = -\beta f(t)V(t)$$

$$\frac{dV(t)}{dt} = \gamma f(t)V(t) - \delta V(t)$$

194 with γ , a new parameter equal to $\rho\beta T_0/c$ and interpreted to be the maximum rate of viral replication. δ can now be
195 interpreted as overall viral elimination rate. This population model was then fitted to viral load data with time using the
196 following form:

$$y_{ij} = f(\varphi_i, t_{ij}) + \varepsilon_{ij}$$

197 where y_{ij} was the viral load from subject i at time t_{ij} , f is the nonlinear model defined above with parameters φ_i , and ε_{ij} the
198 residual between the model prediction and the observed data.

199

200 Four parameters were estimated: the initial viral load at symptom onset (V_0), β , δ and γ . Interindividual variability was
201 estimated for V_0 , β and δ with each assumed to follow a log-normal distribution. Viral loads were log transformed and the
202 residual error was assumed to follow a normal distribution. Parameter estimation by maximum likelihood was undertaken
203 using the stochastic approximation expectation maximization (SAEM) in NONMEM version 7.4²⁰. Model evaluation was
204 undertaken by analysis of normalised prediction distribution errors (NPDE) and visual predictive checks (VPC)²¹. Viral
205 loads below the limit of detection (LOD) were included by integrating the density function from minus infinity to the limit
206 of detection to yield a probability of the data being below the LOD (“M3 Method”)²².

207 In some participants, multiple samples were taken at the same time point (either different sampling site or the same sample
208 assayed by more than one method). In this case a common residual error term was used to allow for modelling one-level
209 nested random effects.

210

211 *Descriptive analysis of viral shedding by sample site*

212 The above model was fitted to data from each sampling site. The resulting parameters were then used to simulate the
213 overall population viral load trajectories. For the respiratory sample sites viral area under the curve (AUC), peak viral load
214 and half-life were derived from the model and plotted *versus* patient covariates.

215 *Covariate analysis and antiviral drug effects modelling*

216 The initial model used only data obtained in untreated patients. A covariate analysis was undertaken testing the influence of
217 sampling site (nasal *versus* oral *versus* lower respiratory tract), sex, age and disease status on either V_0 , β or δ . Covariates
218 were retained in the model based on the likelihood ratio test with a threshold level of significance of $p < 0.01$, and if the
219 same covariate addition to V_0 , β or δ all gave significant improvement to model fit then the model with the largest decrease
220 in -2 log likelihood (NONMEM objective function value (OFV)) was chosen. For the final model viral area under the curve
221 (AUC), peak viral load and half-life were derived and plotted versus patient covariates.

222

223 Using the final demographic model, data from patients undergoing antiviral treatment (antiviral drug quality 1) were added.
224 A univariable analysis was performed, testing each drug's ability to increase δ . Drugs showing significant improvement in
225 model fit ($p < 0.01$), according to the likelihood ratio test, were then included in the final multivariable model.

226

227 **Simulations based on the antiviral pharmacology model**

228 Simulations were performed to explore the change in viral trajectories for different time points of therapy initiation: Day 1
229 after symptom onset, Day 3, Day 7 and Day 10. Interferon and ribavirin monotherapy along with the combination therapy
230 interferon plus ribavirin were explored this way. A dummy population of 5100 subjects with ages uniformly distributed
231 across 50 to 100 years, consisting of an equal ratio of males and females was created. Each regimen was simulated using
232 the entire population, assuming sampling from the upper respiratory tract or nose for a time window of 14 days.
233 Comparisons of the sample size required to detect a significant difference in the proportion of undetectable virus between
234 antiviral and no treatment were made after 7 days of treatment with a 90% power and alpha level of $p < 0.05$ for antivirals
235 starting at Days 1, 3 and 7 post symptom onset.

236 RESULTS

237 Results of the systematic search are given in Figure 1, and details of included papers in Table 1. Individual patient-level
238 data were extracted from 45 articles reporting viral loads and/or PCR Ct values with time since symptom onset. Of these 32
239 papers either reported antiviral participant-level drug histories, or these were provided by the corresponding author. The
240 full dataset contained 645 individuals contributing 6316 viral load samples. The majority of samples (n) were taken from
241 the respiratory tract: nasopharyngeal (315 individuals, $n=2208$), oropharyngeal or saliva (381 individuals, $n=2144$) and
242 lower respiratory tract (81 individuals, $n=799$). The other reported samples sites were stool/rectal swabs (99 individuals,
243 $n=655$), blood/plasma (42 individuals, $n=258$), urine (31 individuals, $n=112$), ocular (16 individuals, $n=50$), breastmilk (4
244 individuals, $n=90$). Metrics of the full data set are given in Supplementary Table S1.

245
246 Full details of the extracted patient-level covariates are given in Table 2. Recording of fever, days on ICU and days
247 ventilated was largely unavailable. Therefore, no further analysis was performed on these variables. However, it was
248 possible to categorise disease status in all drug quality 1 and 2 papers, either through reports in the manuscript or by
249 contacting corresponding authors. Overall, most patients had mild disease 376 (66.8%), whereas 79 (14.0%) patients had
250 moderate and 84 (14.9%) severe disease. In total 24 (4.3%) asymptomatic patients were reported. The distribution of
251 recorded drug therapies, available for drug quality 1 data and respiratory site samples, is summarised in Supplementary
252 Table S2. Sixty-seven of these patients did not receive antivirals.

253
254 The NLME model fits to the overall data, stratified by sampling site, are provided in Supplementary Table S3 and
255 Supplementary Figure S1. Simulations from the models for each sampling site showing the expected viral load trajectory
256 along with the predicted proportion of samples, that would be below the limit of detection are given in Figure 2. For
257 respiratory sites model-derived AUC, peak viral load and half-life is given in Supplementary Figure S2

258
259 Data on a total of 354 patients with respiratory and/or stool/rectal sampling and drug quality 1 or 2 were available. A forest
260 plot of the parameter estimates from the Cox proportional hazards regression model is provided in Figure 3. Viral clearance
261 was fastest from upper respiratory tract samples and slowest from stool. More sensitive assays (with lower detection limits)

262 were associated with longer time to viral clearance and viral clearance was faster in females, younger patients and those
263 who were asymptomatic.

264

265 Regarding antiviral therapies, only remdesivir (adjusted hazard ratio (AHR) = 9.19, $p < 0.001$) and interferons (AHR = 2.20,
266 $p = 0.015$) were independently associated with faster viral clearance. The effect of interferon alpha and beta (Supplementary
267 Figure S3) was similar and hence these were combined. Lopinavir/ritonavir, ribavirin and interferons were most used and
268 also most used in combination. Adding interaction terms for interferon plus lopinavir/ritonavir, interferon plus ribavirin and
269 lopinavir/ritonavir plus ribavirin in the Cox proportional hazard regression analysis showed a trend towards synergy
270 between interferons and ribavirin in the full dataset (AHR = 6.04, $p = 0.006$ Figure 3), as well as in the additional analysis
271 taking in quality assessments to account for potential bias: respiratory data limited to drug quality and in data limited to
272 only viral load quality 1 data (Supplementary Figure S4 and Figure S5). Median sampling frequency in the main survival
273 dataset was 1 day but there was a skewed distribution of sampling frequencies with the mean being 1.9 days and 4.8% of
274 sampling frequencies being greater than 3 days. The main analysis was repeated excluding events with sampling
275 frequencies over 3 days to check for potential bias caused by interval censoring, but the main effect sizes were similar
276 (Figure S6).

277

278 Covariate relationships and drug effects were explored through NLME modelling with parameter estimates of the model
279 given in Supplementary Table S4 along with visual predictive checks and NPDEs in Figure 4 and Supplementary Figure S7
280 and visualization of viral area under the curve, peak viral load and half-life derived from the final model in Supplementary
281 Figure S8. Drug effects were estimated to increase δ . Drug regimens containing interferon ($\Delta\text{OFV} = -25.5$, $p < 0.001$),
282 lopinavir/ritonavir ($\Delta\text{OFV} = 9.97$, $p = 0.0016$) and ribavirin ($\Delta\text{OFV} = -22.2$, $p < 0.001$) each improved model fit and so were
283 taken forward to the final multivariable drug model. The estimated small lopinavir/ritonavir effect on delta, although
284 showing significant model improvement in the likelihood ratio test, did not prove to be robustly detected in the bootstrap
285 analysis, with the interval crossing the value consistent with no drug effect (Table S4). Implementing an additional synergy
286 term, as detected in the Cox proportional hazard model, did not improve the NLME model.

287

288 The final model was then used to simulate expected viral trajectories from upper respiratory sampling sites for interferon,
289 and ribavirin monotherapy as well as interferon plus ribavirin combination started at 1, 3, 7 and 10 days post symptom
290 onset (Figure 5). The sample sizes for hypothetical Phase II trials to detect significant differences in viral load versus no
291 treatment after 7 days of therapy are given in Supplementary Table S5.

292

293 DISCUSSION

294 This systematic review and individual level meta-analysis has identified viral load trajectories from 645 individuals aged
295 from the first month of life to 100 years. Data from all major sampling sites showed, that: following symptom onset in most
296 patients, upper respiratory tract viral load has peaked and is declining, whereas in the lower respiratory tract viral load
297 peaks 2-3 days after symptom onset; virus is detectable in stool for at least 2 weeks in 75% of individuals, and virus is
298 detected in low levels in blood, urine, ocular secretions and breast milk (Figure 2). In addition to simulating the expected
299 trajectory of viral load at each site, we were able to simulate the percentage of samples expected to be below a typical
300 detection limit of 10 copies/mL (Figure 2). From this it can be seen, that from day 10 post symptom onset over a quarter of
301 upper respiratory samples have undetectable viral load. This emphasises the importance of early antiviral therapy, and for
302 Phase II trials using viral load as an endpoint to commence therapy in the first few days of symptom onset in order to
303 reliably differentiate antiviral effects from natural viral decline (Figure 5, Supplementary Table S5).

304

305 Although we followed PRISMA guidelines on individual patient-level meta-analysis methods, registered our review with
306 PROSPERO and prospectively published our analysis protocol prior to finalising our search, by including data from case
307 reports, case series and clinical trials it could be argued that the heterogeneous inclusion criteria of these data may bias the
308 treatment effects we estimated. We therefore repeated the primary analysis on subsets of the data based on sampling site,
309 data quality and sampling frequency (Supplementary Figures S4-6) finding that the main effects were consistent. It should
310 be noted that by far the largest drug quality 1 dataset was the clinical trial from Hung et al⁹ with 127 patients randomised to
311 either lopinavir/ritonavir versus lopinavir/ritonavir plus ribavirin plus interferon β , and our second largest drug quality 1
312 group was those confirmed to have received no antiviral drugs (67 patients). In total our NLME dataset contained data on
313 83 patients receiving interferons, 187 patients receiving lopinavir/ritonavir, and 99 patients receiving ribavirin either alone
314 or in combination (Table S2). Therefore, whilst consistency in results with various subgroup analyses indicate confounding

315 related to heterogeneous data is unlikely to have biased our main findings, the heterogeneity in drug and drug combination
316 studies meant modelling was required to tease out individual drug effects.

317

318 A heterogeneous range of antivirals, administered in different combinations, was observed in our data (Supplementary
319 Table S2) meaning multivariable modelling of time to viral clearance was used to tease out individual drug effects. No
320 antiviral activity was seen for chloroquine/hydroxychloroquine, azithromycin, lopinavir/ritonavir, umifenovir and
321 thymalfasin. However, remdesivir and interferons were both independently associated with shorter time to viral clearance
322 (Figures 3, S4 and S5). Remdesivir did not however significantly decrease δ in the NLME model, but this is likely due to
323 the low number of included patients.

324

325 Our most interesting finding is the promising antiviral activity of interferons, possibly due to low endogenous interferon
326 levels induced by SARS-CoV-2^{23, 24}. Interferons (alpha and beta) have shown extensive *in vitro* activity against Severe
327 acute respiratory syndrome-1 (SARS-CoV-1) and Middle East respiratory syndrome coronavirus (MERS-CoV)²⁵.
328 ²⁶However, this has not translated into clinical effectiveness in MERS-CoV²⁵, although results from one trial are still
329 pending²⁷. Although recent data suggests interferon beta may be more potent than alpha against SARS-CoV-2 *in vitro*²⁸,
330 possibly due to higher selective indices for interferon-beta 1b, upon finding similar effects of interferon alpha and beta in
331 our primary analysis (Figure S3), we decided to combine the interferon effect to better explore drug combinations. In the
332 Cox proportional hazard analysis, consistent across data qualities and sampling site combinations, we found either a
333 significant or trend towards significant synergistic activity of interferon plus ribavirin (Figures 3, 4, S4). An extensive body
334 of literature exists to show both interferon alpha and beta are synergistic with ribavirin *in vitro* against both SARS-CoV-1
335 and MERS-CoV²⁵. This synergy, however, was not confirmed when tested in the NLME analysis, indicating that the
336 detected synergistic effect from the time to viral clearance analysis might be confounded. Correlations in the timing for
337 start of drug treatment could be one confounder that is corrected for in the NLME approach. The time-dependant analysis
338 from the NLME model suggests an additive effect for interferon and ribavirin, rather than a synergistic effect. Thus,
339 combining interferons with a nucleoside analogue, possibly remdesivir or favipiravir as less toxic alternatives to ribavirin,
340 is a potentially promising combination for viral load suppression. In our secondary analysis, we included interferon plus
341 ribavirin in the NLME model and simulations show that virus should be suppressed 2-3 days faster compared to no
342 treatment (Figure 5). However, it must be noted that recent evidence from the WHO SOLIDARITY trial shows that

343 interferons were associated with a trend to increased mortality²⁹ whereas an unpublished press release reports inhaled
344 interferon- β to be beneficial³⁰. There is a clear need for a well-designed Phase II trial on interferons in early disease to
345 confirm or refute the signal seen in our data.

346

347 Another main finding of our work was the limited antiviral effect of lopinavir/ritonavir, in addition to its lack of significant
348 synergistic effect with either ribavirin or interferons. The protease inhibitor lopinavir had a modest but consistent *in vitro*
349 activity against the major coronaviruses, including SARS-CoV-2, although activity is confined to concentrations at the
350 upper end of the clinically achievable range¹. Whilst lopinavir significantly improved model fit when increasing δ , the
351 bootstrap lower boundary crossed the threshold of no drug effect (Table S4), and our simulations suggest monotherapy
352 studies would require well over 500 participants per arm just to show antiviral activity. As recent Phase III trials have now
353 conclusively shown, lopinavir/ritonavir is ineffective in monotherapy^{29, 31}. It remains to be seen whether
354 lopinavir/ritonavir may be useful in combinations, however. In SARS-CoV-1 lopinavir/ritonavir plus ribavirin was found
355 to be synergistic *in vitro* and when initiated immediately upon diagnosis led to a significant decrease in mortality compared
356 to historical controls^{32, 33}. Early post-exposure prophylaxis against Middle East Respiratory Syndrome (MERS-CoV) in
357 healthcare workers showed that lopinavir/ritonavir plus ribavirin reduced the incidence of infection from 28% to 0%³⁴. The
358 lopinavir/ritonavir plus ribavirin combination has therefore been the basis for many clinical trials and treatment protocols,
359 but our findings suggest that it may not be as useful in SARS-CoV-2 (Figure 3).

360

361 The antiviral effects of remdesivir *in vitro* are well established and despite only being able to extract individual patient-
362 level data on six patients, it produced a significantly faster viral clearance in the primary analysis (Figure 3). Despite in
363 some cases showing promising *in vitro* activity, we did not find significant antiviral effects of azithromycin,
364 chloroquine/hydroxychloroquine, thymalfasin or umifenovir. In the case of hydroxychloroquine and azithromycin the raw
365 viral load data from the heavily criticised study by Gautret et al³⁵ was included, but contrary to the original analysis we
366 found no clinical antiviral activity of either drug and, in the case of hydroxychloroquine, a trend towards slower viral
367 clearance. The reason for this difference in interpretation appears to stem from using time since symptom onset as opposed
368 to time since starting drug and with untreated patients being monitored from an earlier day-post symptom onset. This
369 example highlights the necessity of accounting for the time course of the infection when analysing viral loads.

370

371 In our secondary NLME analysis the simplified target cell limited model provided a good fit to data from each sampling
372 site. In many cases this approximated a mono-exponential decay, but in others, particularly in lower respiratory tract, there
373 was a pronounced peak in the first days following symptom onset. The model was stable with high inter-individual
374 variability on V_0 and β , reflecting the fact that relative changes in these parameters lead to the initial part of the curve either
375 rising then falling (in situations when $V_0 \approx -\beta$) or approximately monoexponentially declining (when $V(0) \gg -\beta$). In
376 addition, we found the model to be less sensitive to changes in γ , meaning it can take a wide range of values with little
377 influence on model fit, hence we did not estimate an inter-individual variability term on it. Increasing age was associated
378 with significantly slower δ , and there was a small effect of male sex also being associated with slower δ (Table S4). The
379 age effect translates to a 5-year-old having a viral decay terminal half-life of 1.0 day, a 47-year-old (median age in our
380 population) 1.18 days and a 90-year-old 1.24 days. Hence a child has an almost 15% faster viral clearance than a middle-
381 aged adult, and almost 20% faster than an elderly person.

382

383 In contrast to authors who have estimated parameters for more mechanistic models³⁶, we estimated all drug effects to
384 increase δ , which implies a mode of action relating to inhibition of viral replication or stimulation of viral clearance
385 mechanisms. Whilst for most of the drugs studied this may be reasonable, entry inhibitors may be more appropriately
386 described by inhibition of γ , which may not be statistically identifiable with the data possible to collect in the clinical
387 setting. Despite this potential limitation, we found similar agents (combinations including interferons and ribavirin) to those
388 identified in the primary analysis of time-to viral clearance.

389

390 The major limitation of our work is the lack of clinical trial data and lack of data on potentially important re-purposing
391 agents such as favipiravir and nitazoxanide and that only one of the authors of a major clinical trial agreed to share their
392 data⁹. Through applying quality assessment criteria on drug history and assay reporting, pre-specifying our analysis in our
393 protocol and PROSPERO registration before undertaking Cox proportional hazards and NLME modelling we aimed to
394 reduce possible bias in the heterogenous data available. Whilst we were able to extract a limited common demographics
395 set, particularly in the high-quality data subset (age, sex, disease severity, antiviral drug histories), our data may be limited
396 by other non-antiviral medications that were not fully reported in the included papers. Furthermore, as many of our
397 included papers were on patients with mild or no symptoms and only contained data on one patient reported to have died,
398 we were unable to study associations of viral load and mortality. Viral load measured by PCR is not necessarily infectious

399 virus, and recently it has been shown that only in samples above 10^7 copies/mL can SARS-CoV-2 be cultured²⁹. Therefore,
400 our data should preferably be used to study viral trajectories in relation to antiviral therapy rather than to infer probability
401 of transmission.

402

403 The detection of viable virus might be overcome through whole genome sequencing and the detection of subgenomic RNA.
404 This has however only been conducted in a single study, included in our review. Woelfel et al.³⁷ showed through E gene
405 subgenomic RNA quantification and relating it to the entire virus genome RNA, that presence of subgenomic RNA
406 fragments can be a hint for active viral replication and thus active infection. More recent studies by Alexandersen et al³⁸
407 and van Kampen et al³⁹ however detected subgenomic RNA up to 22 days after onset of symptoms. It is postulated this was
408 related to subgenomic RNA being rather stable and associated with cellular membranes and thus detection of subgenomic
409 RNAs in clinical samples does not necessarily indicate viral activity. Future controlled studies of subgenomic RNA levels
410 in patients on and off antiviral therapies are urgently required to better understand this potential biomarker of drug effect.

411

412 In conclusion, this individual patient level meta-analysis has yielded useful insights into SARS-CoV-2 viral dynamics. A
413 model-based description of viral trajectories in different sampling sites has been elucidated, and we have found covariates
414 such as increasing age, disease severity and male sex to be associated with slower viral clearance. Our review firmly
415 establishes a role for early viral suppression in the management of SARS-CoV-2 and an important signal as to the possible
416 benefits of interferons as a component of antiviral therapy has been found. It has been shown that viral dynamic models
417 such as ours can increase the power to detect drug effects due to their utilisation of serial measures⁴⁰ and our model should
418 be useful to others in both the design and analysis of future Phase II trials, hence the model code and raw data from this
419 analysis is made available.

420

421 DATA AVAILABILITY

422 The final dataset is available at: <https://github.com/ucl-pharmacometrics/SARS-CoV-2-viral-dynamic-meta-analysis>

423

424 CODE AVAILABILITY

425 Model code is available at: <https://github.com/ucl-pharmacometrics/SARS-CoV-2-viral-dynamic-meta-analysis>

426

427

428 FIGURE LEGENDS

429 Figure 1: PRISMA diagram detailing the systematic search results.

430

431 Figure 2: Model-predicted viral load trajectories at each sample site studied.

432 Black lines are the median predictions, with shaded areas representing the 95% prediction interval. The percentage of
433 samples that are predicted to be below a typical limit of detection (10 copies/mL) are given in 2-daily time bins on each
434 plot.

435

436 Figure 3: Multivariable Cox proportional hazard results on all drug quality 1 and drug quality 2 data from respiratory and
437 stool/rectal sampling sites. Adjusted hazard ratios exceeding 1 indicate virus being more likely to become undetectable.

438

439 Figure 4: Visual predictive checks for the NLME model fitted to viral load data to each sampling

440 site. For each site a plot of model simulations compared with observations is given for both the continuous data (upper) and
441 the fraction of samples below the limit of detection (lower). Black circles are observed viral loads, purple shaded area is the
442 95% prediction interval of the simulated 2.5th and 97.5th percentile for comparison with the observed 2.5 and 97.5th
443 percentile (dashed lines). The blue shaded area is the 95% prediction interval of the 50th percentile to compare with the
444 continuous black line. In the lower plot the observed proportion of samples below the lower limit of detection (LLOD) are
445 shown as a black line and compared with the 95% prediction interval of the model predicted proportion of samples below
446 the LLOD (green shaded area).

447

448 Figure 5: Simulated viral load trajectories.

449 Simulations with a dummy population equally distributed between 50 and 100 years, and equal male/female ratio were
450 performed for each scenario. Drugs were started at day 1 (blue), day 3 (orange), day 7 (green) or day 10 (red) post
451 symptom onset. Mean black line and error bars represent simulations of the dummy population without drug treatment.
452 Coloured mean lines and error bars represent the respective drug regimen. Percentage values represent expected proportion
453 of samples below the limit of detection for no drug (black) versus drug therapy (coloured) at each time point.

REFERENCES

1. Arshad U, *et al.* Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. *Clin Pharmacol Ther.* (2020)
2. To KK, *et al.* Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis* **20** 565-574. (2020)
3. He X, *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med* **26** 672-675. (2020)
4. Rajpal A, Rahimi L, Ismail-Beigi F. Factors Leading to High Morbidity and Mortality of COVID-19 in Patients with Type 2 Diabetes. *J Diabetes.* (2020)
5. Fishman JA, Grossi PA. Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve. *Am J Transplant* **20** 1765-1767. (2020)
6. Zheng S, *et al.* Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ* **369** m1443. (2020)
7. Kamal MA, *et al.* A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression. *Antimicrob Agents Chemother* **59** 5388-5395. (2015)
8. Kim JY, *et al.* Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea. *J Korean Med Sci* **35** e86. (2020)
9. Hung IF, *et al.* Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet* **395** 1695-1704. (2020)
10. Recovery trial. Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on lopinavir-ritonavir. 2020 [cited 29.06.2020] Available from: https://www.recoverytrial.net/files/lopinavir-ritonavir-recovery-statement-29062020_final.pdf
11. Stewart LA, *et al.* Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. *JAMA* **313** 1657-1665. (2015)

12. Rohatgi A. Webplotdigitizer: Version 4.2. 2019 [cited]Available from: <https://automeris.io/WebPlotDigitizer>.
13. Vogels CBF, *et al.* Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR primer-probe sets. *medRxiv* 2020.2003.2030.20048108. (2020)
14. Chu DKW, *et al.* Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. *Clin Chem* **66** 549-555. (2020)
15. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. *Biometrika* **81** 515-526. (1994)
16. R Core Team. A language and environment for statistical computing (version 3.6.3). R Foundation for Statistical Computing, Vienna, Austria. 2019 [cited]Available from:
17. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza A virus infection in humans. *J Virol* **80** 7590-7599. (2006)
18. Anguelova M, Karlsson J, Jirstrand M. Minimal output sets for identifiability. *Math Biosci* **239** 139-153. (2012)
19. Kim KS, *et al.* Modelling SARS-CoV-2 Dynamics: Implications for Therapy. *medRxiv* 2020.2003.2023.20040493. (2020)
20. Beal SLS, L.B.; Boeckmann,A.J.; Bauer, R.J. NONMEM 7.4 users guides. (1989 -2018) [cited]Available from: 10.1128/AAC.00069-15
21. Nguyen TH, *et al.* Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics. *CPT Pharmacometrics Syst Pharmacol* **6** 87-109. (2017)
22. Beal SL. Ways to Fit a PK Model with Some Data Below the Quantification Limit. *Journal of Pharmacokinetics and Pharmacodynamics* **28** 481-504. (2001)
23. Blanco-Melo D, *et al.* Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* **181** 1036-1045 e1039. (2020)

24. Chu H, *et al.* Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. *Clin Infect Dis.* (2020)
25. Zeitlinger M, *et al.* Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. *Clin Pharmacokinet.* (2020)
26. Sheahan TP, *et al.* Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nat Commun* **11** 222. (2020)
27. Arabi YM, *et al.* Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. *Trials* **19** 81. (2018)
28. Yuan S, *et al.* Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). *Viruses* **12**. (2020)
29. Pan H, *et al.* Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. *medRxiv* 2020.2010.2015.20209817. (2020)
30. Synairgen plc. Interim results for the six months ended 30 June 2020. 2020 [cited]Available from: <https://www.synairgen.com/wp-content/uploads/2020/09/200929-Synairgen-Interim-Results-final.pdf>
31. Recovery Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet.* (2020)
32. Chu CM, *et al.* Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. *Thorax* **59** 252-256. (2004)
33. Chan KS, *et al.* Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. *Hong Kong Med J* **9** 399-406. (2003)
34. Park SY, *et al.* Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. *J Hosp Infect* **101** 42-46. (2019)

35. Gautret P, *et al.* Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents* **56** 105949. (2020)
36. Goncalves A, *et al.* Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load. *CPT Pharmacometrics Syst Pharmacol.* (2020)
37. Wolfel R, *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature* **581** 465-469. (2020)
38. Alexandersen S, Chamings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. *medRxiv* 2020.2006.2001.20119750. (2020)
39. van Kampen JJA, *et al.* Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants. *medRxiv* 2020.2006.2008.20125310. (2020)
40. Laouenan C, Guedj J, Mentre F. Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach. *BMC Med Res Methodol* **13** 60. (2013)
41. Kam KQ, *et al.* A Well Infant With Coronavirus Disease 2019 With High Viral Load. *Clin Infect Dis* **71** 847-849. (2020)
42. Liu Y, *et al.* Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci* **63** 364-374. (2020)
43. Lim J, *et al.* Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. *J Korean Med Sci* **35** e79. (2020)
44. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. *Lancet Infect Dis* **20** 411-412. (2020)
45. Zhang W, *et al.* Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerg Microbes Infect* **9** 386-389. (2020)
46. Xu T, *et al.* Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19. *Int J Infect Dis* **94** 68-71. (2020)

47. Chen W, *et al.* Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. *Emerg Microbes Infect* **9** 469-473. (2020)
48. Young BE, *et al.* Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. *JAMA*. (2020)
49. Shen C, *et al.* Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA*. (2020)
50. Wan R, Mao ZQ, He LY, Hu YC, Wei C. Evidence from two cases of asymptomatic infection with SARS-CoV-2: Are 14 days of isolation sufficient? *Int J Infect Dis* **95** 174-175. (2020)
51. Lescure FX, *et al.* Clinical and virological data of the first cases of COVID-19 in Europe: a case series. *Lancet Infect Dis* **20** 697-706. (2020)
52. Xu Y, *et al.* Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat Med* **26** 502-505. (2020)
53. Han MS, *et al.* Sequential analysis of viral load in a neonate and her mother infected with SARS-CoV-2. *Clin Infect Dis*. (2020)
54. Wyllie AL, *et al.* Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. *medRxiv* 2020.2004.2016.20067835. (2020)
55. Cheng CY, *et al.* Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. *J Microbiol Immunol Infect* **53** 488-492. (2020)
56. Yang Y, *et al.* Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. *medRxiv* 2020.2002.2011.20021493. (2020)
57. Yang JR, *et al.* Persistent viral RNA positivity during the recovery period of a patient with SARS-CoV-2 infection. *J Med Virol*. (2020)
58. Covid- Investigation Team. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. *Nat Med* **26** 861-868. (2020)

59. Lui G, *et al.* Viral dynamics of SARS-CoV-2 across a spectrum of disease severity in COVID-19. *J Infect* **81** 318-356. (2020)
60. Hu Y, *et al.* A report of three COVID-19 cases with prolonged viral RNA detection in anal swabs. *Clin Microbiol Infect* **26** 786-787. (2020)
61. Seah IYJ, *et al.* Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients. *Ophthalmology* **127** 977-979. (2020)
62. Liu WD, *et al.* Prolonged virus shedding even after seroconversion in a patient with COVID-19. *J Infect* **81** 318-356. (2020)
63. Xing YH, *et al.* Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019. *J Microbiol Immunol Infect* **53** 473-480. (2020)
64. Qian GQ, *et al.* Duration of SARS-CoV-2 viral shedding during COVID-19 infection. *Infect Dis (Lond)* **52** 511-512. (2020)
65. Kim ES, *et al.* Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. *J Korean Med Sci* **35** e142. (2020)
66. Colavita F, *et al.* SARS-CoV-2 Isolation From Ocular Secretions of a Patient With COVID-19 in Italy With Prolonged Viral RNA Detection. *Ann Intern Med* **173** 242-243. (2020)
67. Hill KJ, *et al.* The index case of SARS-CoV-2 in Scotland. *J Infect* **81** 147-178. (2020)
68. Huang Y, *et al.* SARS-CoV-2 Viral Load in Clinical Samples from Critically Ill Patients. *Am J Respir Crit Care Med* **201** 1435-1438. (2020)
69. Zhou R, *et al.* Viral dynamics in asymptomatic patients with COVID-19. *Int J Infect Dis* **96** 288-290. (2020)
70. Qi L, *et al.* Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study. *Int J Infect Dis* **96** 531-537. (2020)
71. Yuan C, *et al.* Viral loads in throat and anal swabs in children infected with SARS-CoV-2. *Emerg Microbes Infect* **9** 1233-1237. (2020)

72. Huang JT, *et al.* Chronological Changes of Viral Shedding in Adult Inpatients with COVID-19 in Wuhan, China. *Clin Infect Dis.* (2020)
73. Kong Y, *et al.* Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma. *Transfus Apher Sci* 102820. (2020)
74. Tam PCK, *et al.* Detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human breast milk of a mildly symptomatic patient with coronavirus disease 2019 (COVID-19). *Clin Infect Dis.* (2020)
75. Yoon JG, *et al.* Clinical Significance of a High SARS-CoV-2 Viral Load in the Saliva. *J Korean Med Sci* **35** e195. (2020)
76. Phan LT, *et al.* Clinical features, isolation, and complete genome sequence of severe acute respiratory syndrome coronavirus 2 from the first two patients in Vietnam. *J Med Virol.* (2020)
77. Klement-Frutos E, *et al.* Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19. *J Infect.* (2020)
78. Gross R, *et al.* Detection of SARS-CoV-2 in human breastmilk. *Lancet* **395** 1757-1758. (2020)

SUPPLEMENTAL FILES

1. Supplemental Material

Table 1 Individual papers included in the Meta-Analysis

Study ID	Country	Sample Type	Assay Gene	No. of Patients	of Sampled Patients	Samples per patient median [min -max]	Treatment	Symptom details	Age, years median (IQR) {R}	Sex M (F)	Ref.
1	SGP	URT, Vn, Un, Re, Br	N, Orflab	2	2	14,28	None	Yes	0.5	1 (1)	41
2	KOR	URT, LRT, Vn, Un, Re	RdRp, E	2	2	98,136	lpvr, other	Yes	55/35	1 (1)	8
3	HKG	URT, LRT, Vn	RdRp	23	23	3 [1-24]	lpvr, riba, Ifn	Yes* (not longitudinal)	62 {37-75}*	13 (10)*	2
4	CHN	URT, LRT	N, Orflab	12	5	2	riba, ifn, other	Yes (not longitudinal)	63 (47-65) [10-72]	8 (4)	42
5	KOR	URT	RdRp	1	1	11	lpvr, azit, other	Yes	54	1 (0)	43
6	CHN	URT, LRT	N	80 (2)	2	30,50	-	-	-	-	44
7	CHN	URT	N, Orflab	17	17	8 [1-17]	-	Yes (not longitudinal)	59 {26-78}	8 (9)	1
8	CHN	URT, Re, Vn	S	16	16	1 [1-3]	-	-	-	-	45
9	FRA	URT	RdRP, E	36	26	7 [3-7]	cqhcq, azit	-	Mean 45 +/- 22	15 (21)	35
10	CHN	URT	N, Orflab	51	50	4 [1-14]	lpvr, Ifn, thym, umif, other	Yes	43 (29-53)	25 (26)	46
11	CHN	URT, Vn, Re	N, Orflab	6	6	9 [2-19]	-	-	-	5(1)	47
12	CHN	URT	N	94	94	3 [1-6]	-	-	46 (33-61)*	47 (47)*	3

Study ID	Country	Sample Type	Assay Gene	No. of Patients	Sampled Patients	Samples per patient median [min -max]	Treatment	Symptom details	Age, years median (IQR) {R}	Sex M (F)	Ref.
13	SGP	URT	N, S, and Orf1ab	18	18	16 [7-25]	lpvr	Yes	47 {31-73}*	9 (9)*	48
14	CHN	URT	-	5	5	6	lpvr, Ifn, other	Yes	{36-73}*	3 (2)	49
15	CHN	URT	Orf1ab	2	2	7,9	lpvr, riba	Yes	19/36	2 (0)	50
16	FRA	URT, Re	RdRp, RdRp-IP1, GAPDH, E,	5	5	11 [5-13]	remd	Yes (not longitudinal)	46 (31-48)	3 (2)	51
17	GER	URT, LRT, Re	RdRP, E	9	9	47 [13-54]	-	Yes	40 (33-49)	8 (1)	37
18	CHN	URT, Re	N, Orf1lab	10	9	11 [2-20]	-	Yes	7 (3-13)	6 (4)	52
19	KOR	URT, Vn, Re, Un	E	2	2	18,33	None	Yes	0.08, neonate	0 (2)	53
20	USA	URT	-	44	19	3 [2-8]	-	-	{23-92}, 61 (mean)*	23 (21)*	54
21	TWN	URT, LRT	RdRp1, RdRp2, E, N	5	5	20 [17-24]	lpvr, None	Yes	52 (50-53)	2 (3)	55
22	CHN	URT, LRT	-	213	13	7 [4-19]	AVT	Yes	52 (2-86)	108 (105)	56
23	CHN	URT	-	1	1	9	inf, cqhcq, other	Yes (not longitudinal)	44	1 (0)	57
24	USA	URT	-	12	12	25 [14-49]	remd, other	Yes (not longitudinal)	53 {21-68}	8 (4)	58
25	HKG	URT, LRT, Vn, Re	-	11	11	9 [2-22]	lpvr, riba, ifn*	Yes	58 (42-70)	7 (4)	59

Study ID	Country	Sample Type	Assay Gene	No. of Patients	Sampled Patients	Samples per patient median [min -max]	Treatment	Symptom details	Age, years median (IQR) {R}	Sex M (F)	Ref.
								(not longitudinal)			
26	CHN	URT, Re	Orf1ab, N	3	3	26 [26-52]	ifn, cqhcq, other	Yes	28 {25-32}	2 (1)	⁶⁰
27	SGP	URT	E	17	17	7 [4-14]	-	Yes*	37 {20-75}*	11 (6)	⁶¹
28	TWN	URT, LRT	N, RdRp, E	1	1	249	-	Yes (not longitudinal)	50	0 (1)	⁶²
29	CHN	URT, Re	-	3	1	35	Ifn and Riba	Yes (not longitudinal)	5 {1.5-6}	2 (1)	⁶³
30	CHN	URT, Re	N, RdRp, E	1	1	63	lpvr, umif, Ifn, other	Yes	47	1 (0)	⁶⁴
31	KOR	URT, LRT	E	28	9	13 [8-33]	lpvr, none	Yes*	40 (28-54) {20-73}	15 (13)	⁶⁵
32	ITA	URT	-	1	1	28	-	Yes	65	0 (1)	⁶⁶
33	GBR	URT	-	1	1	13	none	Yes	51	1 (0)	⁶⁷
34	CHN	URT, LRT, Co, Vn, Un, Re	-	16	16	53 [27-106]	-	-	59.5 {26-79}*	13 (3)*	⁶⁸
35	HKG	URT	RdRp	127	127	8 [4-8]	lpvr, riba, ifn	-	51.5 {31.0-62.5}	68 (59)	⁹
36	CHN	URT	N	31	19	2 [1-5]	NA	-	41 {28-60}*	10 (21)	⁶⁹
37	CHN	URT	Orf1ab	147	61	2 [1-6]	AVT	Yes	42.0 (35.0-54.0) {19-81}*	67 (80)	⁷⁰


Study ID	Country	Sample Type	Assay Gene	No. of Patients	Sampled Patients	Samples per patient median [min -max]	Treatment	Symptom details	Age, years median (IQR) {R}	Sex M (F)	Ref.
38	CHN	URT, Re	Orf1ab	54	13	12 [7-20]	NA	Yes	6.8 {2.7-11.7}*	37 (17)	⁷¹
39	CHN	URT	Orf1ab	308	10	9 [7-11]	Lpvr, ifn, riba, cqhcq	Yes	63.5 {45-81}*	151 (157)	⁷²
40	CHN	URT	-	1	1	5	other	Yes	100	1 (0)	⁷³
41	AUS	URT, Br	E	2	2	24 [20-28]	none	Yes	0.7/40	1 (1)	⁷⁴
42	KOR	URT, LRT, Un	RdRp	2	2	25	lpvr, cqhcq	Yes	46/65	0 (2)	⁷⁵
43	VNM	URT	RdRp	2	2	2,13	other	Yes	65/27	2 (0)	⁷⁶
44	FRA	URT, LRT, Vn, Re	E	1	1	27	lpvr	-	-	1 (0)	⁷⁷
45	GER	Br	N, Orf1lab	2	2	32,50	NA	Yes	-	0 (2)	⁷⁸

br = breastmilk, Co = conjunctiva, LRT = lower respiratory tract, Re = faecal/rectal/anal, Un = urine, URT = upper respiratory tract, Vn = venous (blood, plasma, serum), - = Not Reported. AVT = anti-viral therapy, cqhcq = chloroquine/ hydroxychloroquine, ifn = interferon, lpvr = lopinavir/ritonavir, remd = remdesivir, riba = ribavarin, umif = umifenivir.


Table 2 Overview extracted variables across different analyses, median [range] (%missing data records). n, number of individuals included.


Descriptive (%missing)	All Data n=645	Cox-PH - Full data set n=354	NLME/ reduced Cox-PH n=317
Age [years]	46 [0.1 – 100] (31.3%)	48 [0.1-100] (0%)	46 [0.1-100] (0%)
Sex [male/female]	217/189 (37%)	215/139 (0%)	182/135 (0%)
ICU admission [yes/no]*	36/371 (36.9%)	8/271 (21.2%)	8/257 (16.4%)
Invasive ventilation [yes/no]*	14/348 (43.9%)	9/262 (23.4%)	5/247 (20.5%)
Death [yes/no]	1/455 (29.3%)	1/330 (6.5%)	1/293 (7.3%)
Disease severity*	(12.7%)	(0%)	(0%)
Asymptomatic	24	19	16
Mild	376	258	239
Moderate	79	52	44
Severe	84	25	18


*There is discord between the reported ICU and mechanical ventilation and disease severity score due to incomplete reporting in some papers. Disease severity was taken from individual reports of disease status in cases where ICU admission and invasive ventilation were not specifically mentioned, and only Disease severity was used in the analyses.




Pattern of viral shedding in different sites









Days after symptom onset